There is a limit to fast-tracking approvals for coronavirus treatments, says Biocon

Companies and governments require time to gather sufficient data from clinical trials to confirm the efficacy of various COVID-19 treatments being tested, says Kiran Mazumdar-Shaw, chairperson and managing director of Biocon.
Fri, Mar 20 20201:36 AM EDT